Jupiter Topco LLC Buys Shares of 94,500 LifeStance Health Group, Inc. $LFST

Jupiter Topco LLC purchased a new stake in LifeStance Health Group, Inc. (NASDAQ:LFST) during the second quarter, according to its most recent filing with the SEC. The firm purchased 94,500 shares of the company’s stock, valued at approximately $1,013,000.

A number of other hedge funds have also recently made changes to their positions in LFST. BlackRock Inc. bought a new stake in LifeStance Health Group during the second quarter valued at about $389,293,000. Silversmith Partners I GP LLC purchased a new position in shares of LifeStance Health Group in the 4th quarter worth approximately $100,842,000. Vanguard Group Inc. raised its stake in shares of LifeStance Health Group by 21.1% during the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after acquiring an additional 3,086,506 shares in the last quarter. Jennison Associates LLC lifted its position in LifeStance Health Group by 38.5% during the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after acquiring an additional 2,843,388 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in LifeStance Health Group by 62.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after acquiring an additional 1,839,465 shares in the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on the company. Barclays increased their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. Wall Street Zen cut LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday. KeyCorp raised their price target on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. JPMorgan Chase & Co. boosted their price target on LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Finally, Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.38.

Insider Activity

In other news, CTO Vukasin Paunovich sold 44,394 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the sale, the chief technology officer directly owned 247,446 shares of the company’s stock, valued at $2,684,789.10. This represents a 15.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert Bessler sold 894,337 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the sale, the director owned 539,763 shares in the company, valued at $5,467,799.19. This trade represents a 62.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 14,671,917 shares of company stock valued at $155,493,415 in the last quarter. Company insiders own 3.50% of the company’s stock.

LifeStance Health Group Price Performance

Shares of LFST opened at $12.73 on Friday. The business’s 50-day moving average is $11.49 and its two-hundred day moving average is $8.80. The company has a market capitalization of $4.94 billion, a P/E ratio of 97.93 and a beta of 1.22. LifeStance Health Group, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $13.15. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.01) EPS. Research analysts predict that LifeStance Health Group, Inc. will post 0.16 earnings per share for the current year.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.